no desc

Real-world usage of Sulfonylureas in Type 2 Diabetes (JADE register)

In 2021, over half a billion people were living with diabetes worldwide, with 90% having type 2 diabetes (T2D). Practice guidelines recommend a patient-centred approach to individualize selection of glucose-lowering drugs (GLDs) in people with T2D. Compared with White populations, Asian patients with T2D had reduced insulin secreting capacity to overcome insulin resistance. Thus, improvement of insulin secretion via insulin secretagogues such as sulphonylureas (SUs) is a popular treatment strategy amongst Asian patients with T2D. Given that 80% of patients with diabetes live in low- and middle-income countries, metformin and SUs included in the World Health Organization Essential Medicine List will remain the mainstay of treatment.

Using data from the Joint Asia Diabetes Evaluation (JADE) register, a data driven quality improvement programme with structured assessment, this study evaluated treatment responses and tolerability/safety issues associated with SU-based therapy in a real-world setting. In Asia, SUs are a popular oral GLD class, often combined with metformin. Good glycemic control and safety profiles associated with the use of SUs, including gliclazide, support their position as a key treatment option in patients with T2D.

To know more : click here

International Diabetes Federation .

IDF Diabetes Atlas. 10th ed. Brussels, Belgium: International Diabetes Federation; 2021. Available at:

SCAC 05/23 DIA 017 MPAD-For the exclusive use of health professional

It can also interest you


May 11, 2023
Cardiovascular Safety in Type 2 Diabetes with Sulfonylureas as Second-Line Drugs


August 29, 2022
The Association Between Sustained HbA1c Control and Long-Term Complications Amo…


August 22, 2022
Prioritizing early glycemic control to reduce microvascular and macrovascular c…
Background Vimeo Live Event

Keep up to date with our content

Subscribe to our newsletter so that you are always up to date with the news.

You can unsubscribe at any time by clicking on the link in our emails.
SERVIER CENTRAL AMERICA AND THE CARIBBEAN, S.A.Edificio Dream Plaza, Costa Del Este, Ciudad de Panamá, Panamá+507-301-0227Todo el contenido de este sitio web, es sólo para los profesionales de la salud y un uso interno del evento.
LogoCopyright © 2022 Servier University by SERVIER CENTRO AMÉRICA Y EL CARIBE, S.A.